Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build
Incyte Corp INCY
$94.79
▼ -0.55%
($-0.52)
Index member:
S&P 500
Open
$95.88
Prev Close
$95.31
Day Range
$94.63 – $96.60
52W Range
$61.11 – $112.29
Market Cap
$19.80B
P/E (TTM)
13.30
Beta
0.80
EPS (TTM)
$7.07
📋 Company Profile
| Industry | Biotechnology |
| Sector | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1993-12-06 |
| Shares Out. | 199,010,000 |
| Website | incyte.com/ ↗ |
| Phone | 13024986700 |
Incyte Corp is a publicly traded company under the ticker symbol INCY on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
33 analysts (2026-05-01)
📰 Latest News for INCY
Incyte Corporation (INCY) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
Incyte Corporation (INCY) Highlights Sustained Efficacy of Opzelura Through Week 24
Incyte's (NASDAQ:INCY) Promising Earnings May Rest On Soft Foundations
Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine
Does Jakafi XR Approval And Pipeline Progress Change The Bull Case For Incyte (INCY)?
Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View Raised